Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been linked to beneficial effects on cardiovascular risk factors, blood pressure, body weight, and lipid profile, according to a substantial body of literature. Significant cardiac and renal benefits with the use of SGLT2 inhibitors have been s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Diabetology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-4540/4/3/22 |
| _version_ | 1797580625098571776 |
|---|---|
| author | Andrej Belančić Sanja Klobučar |
| author_facet | Andrej Belančić Sanja Klobučar |
| author_sort | Andrej Belančić |
| collection | DOAJ |
| description | Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been linked to beneficial effects on cardiovascular risk factors, blood pressure, body weight, and lipid profile, according to a substantial body of literature. Significant cardiac and renal benefits with the use of SGLT2 inhibitors have been shown in patients with type 2 diabetes, as well as in those with heart failure and/or chronic kidney disease (CKD), regardless of diabetes status, in subsequent large cardiovascular outcome trials. Thus, SGLT2 inhibitors have become a mainstay of therapy for type 2 diabetes in patients with established cardiovascular disease and CKD due to their benefits for the heart and kidneys. Based on data from randomized controlled trials and meta-analyses, this article attempts to present a thorough review of the mechanism of action, as well as the benefits of SGLT2 inhibitors for cardiac and renal protection. On the basis of a growing body of literature on diabetes and other conditions, clinical practice guidelines have been updated to suggest the use of SGLT2 inhibitors in specific patient populations. These modifications will also be concisely described, based on evidence-based medicine principles. |
| first_indexed | 2024-03-10T22:53:30Z |
| format | Article |
| id | doaj.art-b40a9403bb7142b09c535e4f6b14b20d |
| institution | Directory Open Access Journal |
| issn | 2673-4540 |
| language | English |
| last_indexed | 2024-03-10T22:53:30Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diabetology |
| spelling | doaj.art-b40a9403bb7142b09c535e4f6b14b20d2023-11-19T10:12:26ZengMDPI AGDiabetology2673-45402023-07-014325125810.3390/diabetology4030022Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and MechanismsAndrej Belančić0Sanja Klobučar1Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, 51000 Rijeka, CroatiaDepartment of Internal Medicine, Division of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Centre Rijeka, 51000 Rijeka, CroatiaSodium-glucose co-transporter 2 (SGLT2) inhibitors have been linked to beneficial effects on cardiovascular risk factors, blood pressure, body weight, and lipid profile, according to a substantial body of literature. Significant cardiac and renal benefits with the use of SGLT2 inhibitors have been shown in patients with type 2 diabetes, as well as in those with heart failure and/or chronic kidney disease (CKD), regardless of diabetes status, in subsequent large cardiovascular outcome trials. Thus, SGLT2 inhibitors have become a mainstay of therapy for type 2 diabetes in patients with established cardiovascular disease and CKD due to their benefits for the heart and kidneys. Based on data from randomized controlled trials and meta-analyses, this article attempts to present a thorough review of the mechanism of action, as well as the benefits of SGLT2 inhibitors for cardiac and renal protection. On the basis of a growing body of literature on diabetes and other conditions, clinical practice guidelines have been updated to suggest the use of SGLT2 inhibitors in specific patient populations. These modifications will also be concisely described, based on evidence-based medicine principles.https://www.mdpi.com/2673-4540/4/3/22antidiabeticantihyperglycemiccardioprotectioncardiovascular outcome trialclinical trialsdiabetes |
| spellingShingle | Andrej Belančić Sanja Klobučar Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms Diabetology antidiabetic antihyperglycemic cardioprotection cardiovascular outcome trial clinical trials diabetes |
| title | Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms |
| title_full | Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms |
| title_fullStr | Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms |
| title_full_unstemmed | Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms |
| title_short | Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms |
| title_sort | sodium glucose co transporter 2 inhibitors as a powerful cardioprotective and renoprotective tool overview of clinical trials and mechanisms |
| topic | antidiabetic antihyperglycemic cardioprotection cardiovascular outcome trial clinical trials diabetes |
| url | https://www.mdpi.com/2673-4540/4/3/22 |
| work_keys_str_mv | AT andrejbelancic sodiumglucosecotransporter2inhibitorsasapowerfulcardioprotectiveandrenoprotectivetooloverviewofclinicaltrialsandmechanisms AT sanjaklobucar sodiumglucosecotransporter2inhibitorsasapowerfulcardioprotectiveandrenoprotectivetooloverviewofclinicaltrialsandmechanisms |